Algernon Health Inc

Company Profile

• Business description

  Algernon Health Inc is a clinical-stage pharmaceutical development company focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), and stroke, including a program utilizing N,N-Dimethyltryptamine (DMT). Drug re-purposing (also known as re-profiling, re-tasking, or therapeutic switching) involves applying approved drugs and compounds to treat diseases. In addition, the Company is entering the Alzheimer's disease (AD) diagnostic market segment and plans to establish a network of dedicated neuroimaging medical clinics in North America, utilizing FDA-cleared, brain-specific PET scanners to focus on early-stage detection of the disease.

• Contact

  601 West Broadway
  Suite 400
  VancouverBCV5Z 4C2
  CAN

  T: +1 604 646-1553

  E: [email protected]

  https://www.algernonhealth.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 August 2026

  Employees

  1